Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

LEVOFLOXACIN

All products: general benefit

Other products in the same Health Canada class (J01MA) — coverage varies; not interchangeable

  • Ciprofloxacin (Cipro): general benefit, Limited Use 533, Not a benefit
  • Moxifloxacin (Avelox): general benefit, Not a benefit
  • Norfloxacin (Noroxin): general benefit, Not a benefit
  • Ciprofloxacin + ciprofloxacin base (Cipro XL): limited Use 394, Not a benefit

Jamp Levofloxacin · DIN 02508451 · 500mg · tablet

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp Levofloxacin · DIN 02508451 Manufacturer: Jamp Pharma Corporation; listing date 2024-09-27 Health Canada: Marketed since 2024-07-19 · brand JAMP LEVOFLOXACIN · ATC J01MA12 LEVOFLOXACIN · form Tablet · route Oral · ingredients LEVOFLOXACIN (LEVOFLOXACIN HEMIHYDRATE) 500 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Levofloxacin: Formulary list price $1.3718/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3718 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99782 · Verify on the e-Formulary ↗ (DIN 02508451)

Source record
DIN 02508451: Jamp Levofloxacin Raw flags: sec3=Y Item: 084000049; group id 134; item number 0226; lccId None; manufacturer id JPC Source form: Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $1.3718; ministry $1.3718 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02508451 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99782
Interchangeable products
Act Levofloxacin · DIN 02315432 · $1.3718 Apo-Levofloxacin · DIN 02284715 · $1.3718 Levaquin · DIN 02236842 · not recorded Mint-Levofloxacin · DIN 02505819 · $1.3718 Novo-Levofloxacin · DIN 02248263 · $1.3718 Riva-Levofloxacin · DIN 02492733 · $1.3718 Sandoz Levofloxacin · DIN 02298643 · $1.3718
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (08:40 Miscellaneous Anti-Infectives) and how they are covered

Matched class: 08:40 Miscellaneous Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): CIPROFLOXACIN, MOXIFLOXACIN HYDROCHLORIDE, NORFLOXACIN, SULFAMETHOXAZOLE & TRIMETHOPRIM, TRIMETHOPRIM 08:40 Miscellaneous Anti-Infectives

CIPROFLOXACIN

· 44 products · Limited Use, codes 533 (1), Listed, not a benefit (3), General benefit (40) · strengths: 10g/100mL, 250mg, 500mg, 750mg · Oral Susp, Tab

MOXIFLOXACIN HYDROCHLORIDE

· 12 products · Listed, not a benefit (1), General benefit (11) · strengths: 400mg · Tab

NORFLOXACIN

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 400mg · Tab

CIPROFLOXACIN HCL & CIPROFLOXACIN BASE

· 2 products · Listed, not a benefit (1), Limited Use, codes 394 (1) · strengths: 500mg · ER Tab

SULFAMETHOXAZOLE & TRIMETHOPRIM

· 9 products · Listed, not a benefit (6), General benefit (3) · strengths: 40mg & 8mg/mL, 400mg & 80mg, 800mg & 160mg · O/L, Tab

TRIMETHOPRIM

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mg, 200mg · Tab

LINEZOLID

· 6 products · Off-Formulary Interchangeable, not an ODB benefit (2), Listed, not a benefit (1), Limited Use, codes 362, 363, 364 (3) · strengths: 2mg/mL, 600mg · Inj-300mL Pk, Tab

CEFEPIME

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g, 2g · Inj Pd-Vial Pk

ERTAPENEM

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial · Inj Pd-Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:40
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS APO-LEVOFLOXACIN (levofloxacin tablets) are indicated for the treatment of adults with bacterial infections caused by susceptible strains of the designated microorganisms in the infections listed below. • To reduce the development of drug-resistant bacteria and maintain the effectiveness of APO- LEVOFLOXACIN and other antibacterial drugs, APO-LEVOFLOXACIN should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. • Upper Respiratory Tract Acute bacterial sinusitis (mild to moderate) due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella (Branhamella) catarrhalis. Restrict the use of APO-LEVOFLOXACIN to settings where no other treatment options exist, and the clinical presentation meets the diagnostic criteria for acute bacterial sinusitis.1 • Lower Respiratory Tract Acute bacterial exacerbations of chronic bron… https://pdf.hres.ca/dpd_pm/00078730.PDF PM date: JUN 24, 2009 Source product: APO-LEVOFLOXACIN; DIN 02284707; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.